Hemangiomas are the most common vascular tumors in infants and children. Some of them can regress on their own, while some require systemic treatment. Cardiotrophin (a non-selective beta-blocker) has replaced hormones as the first-line treatment. Its possible mechanism of action is to cause vasoconstriction, to reduce the expression of VEGF and bFGF by downregulating the RAF/pro-synuclein-activated protein kinase pathway, and to promote capillary endothelial cell apoptosis. Superficial hemangiomas, especially facial hemangiomas, often affect the aesthetics of the face, causing anxiety and urgency for treatment in the patient’s family. Timolol (timolol) is a non-selective beta-blocker of the same type as takayasu, and its eye drops have been used to treat glaucoma. Pope and Chakkittakandiyil at Toronto Children’s Hospital in Canada tried 0.5% timolol maleate gel for 6 superficial hemangiomas of the head and neck, evaluated independently by 2 investigators twice daily for 4 weeks, 8 weeks and at the end of treatment. 3 cases were proliferating hemangiomas, 2 were in the stable phase and 1 was in the regression phase. No local or systemic adverse effects were observed. Timolol was confirmed to be safe and effective in superficial hemangiomas and in hemangiomas requiring long-term treatment. The results were better and faster in those who used the drug early (1-6 months). Krol AL et al. of Oregon Health and Science University are also conducting a clinical trial of locally applied 0.5% timolol maleate aqueous solution for the treatment of proliferating infantile hemangiomas, with the aim of evaluating the efficacy of locally applied 0.5% timolol maleate aqueous solution for the treatment of small, uncomplicated infantile hemangiomas. It was administered as 2 to 3 drops, applied to the surface of the hemangioma twice daily. A placebo group was also established as a control, and the efficacy of the drug was objectively evaluated after 6 months. Inclusion criteria: 1 to 8 months, hemangioma of the scalp, extremities or trunk, less than 3 cm in diameter. exclusion criteria: hemangioma of the face, genitals, perineum, hands, fingers, toes, and toes; PHACES syndrome; hemangioma larger than 3 cm or ulceration; allergy to β-blockers; history of asthma; renal impairment; cardiac disease; hypoglycemia; taking drugs contraindicated with β-blockers. The advantages of 0.5% timolol maleate gel (or timolol maleate liquid, trade name: Timoxinan) are that it is easy to use, effective for small superficial hemangiomas, and almost free of adverse effects.